A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in ...

Browser fingerprinting is a sneaky way your web activity is tracked, and no matter what browser you use, it's probably ...

Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now ...

Accuray Incorporated ( NASDAQ: ARAY) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT ...

WHO’s classification of hepatitis D virus as carcinogenic raises urgent questions for vaccination, screening, and treatment ...

Dan and Dani, long regarded as a harmonious duo during their weekly reviews of The Block houses, have had a heated clash over the design choices in several contestants' houses. The tension arose ...

While you may have been distracted by Apple’s new product releases and interesting operating system enhancements, the company also quietly a powerful new security feature this week: Memory Integrity ...

Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple ...

All the upcoming PS5 games to expect this October and further afield, from The Outer Worlds 2 to Little Nightmares 3 ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat ...